FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313887560> ?p ?o ?g. }

• W4313887560 endingPage "511" @default.
• W4313887560 startingPage "510" @default.
• W4313887560 abstract "One of the most vexing problems in clinical electrophysiology practice is how to prevent recurrent shocks in patients with implantable cardioverter-defibrillators (ICD). Although ICDs provide lifesaving therapies for patients at high risk for sustained ventricular arrhythmias, recurrent ICD shocks are associated with a worse quality of life and increased mortality. 1 Connolly S.J. Dorian P. Roberts R.S. et al. Comparison of β-blockers, amiodarone plus β-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC study: a randomized trial. JAMA. 2006; 295: 165-171 Crossref PubMed Scopus (606) Google Scholar , 2 Back S.H. Kowey P.R. Strategies to reduce recurrent shocks due to ventricular arrhythmias in patients with an implanted cardioverter-defibrillator. Arrhythm Electrophysiol Rev. 2019; 8: 99 Crossref PubMed Scopus (3) Google Scholar , 3 Abboud J. Ehrlich J.R. Antiarrhythmic drug therapy to avoid implantable cardioverter defibrillator shocks. Arrhythm Electrophysiol Rev. 2016; 5: 117 Crossref PubMed Scopus (12) Google Scholar Drugs to mitigate the risk of recurrent shocks frequently are ineffective or toxic, and ablation has significant risk, especially in older patients with a high disease burden. Although the literature is replete with studies of various drugs that have been used to prevent antitachycardia pacing, shocks, and death, no chemical entity has gained regulatory approval for this very important indication. Because most patients who suffer frequent ICD shocks have cardiomyopathy with reduced systolic function and/or renal impairment, amiodarone has become the default pharmacologic option. But how good and safe is amiodarone in this vulnerable patient population? Despite randomized trials carried out years ago that supported its utility, questions about the ultimate value of amiodarone linger. Single beta-blocker or combined amiodarone therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy—defibrillator patients: Insights from the German DEVICE registryHeart RhythmVol. 20Issue 4PreviewBecause of its antiarrhythmic potency and due to the lack of alternatives, amiodarone is often used for antiarrhythmic therapy in patients with implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy–defibrillator systems. To date, robust data on the safety and clinical benefit of amiodarone therapy in these patients are missing. Full-Text PDF" @default.
• W4313887560 created "2023-01-10" @default.
• W4313887560 creator A5001241147 @default.
• W4313887560 creator A5041291871 @default.
• W4313887560 date "2023-04-01" @default.
• W4313887560 modified "2023-10-17" @default.
• W4313887560 title "Amiodarone for the prevention of shocks and death in patients with implantable cardioverter-defibrillators: Hero or villain?" @default.
• W4313887560 cites W2119818163 @default.
• W4313887560 cites W2518105186 @default.
• W4313887560 cites W2900816551 @default.
• W4313887560 cites W2944603869 @default.
• W4313887560 cites W3105003765 @default.
• W4313887560 cites W4310937029 @default.
• W4313887560 doi "https://doi.org/10.1016/j.hrthm.2023.01.006" @default.
• W4313887560 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36634902" @default.
• W4313887560 hasPublicationYear "2023" @default.
• W4313887560 type Work @default.
• W4313887560 citedByCount "0" @default.
• W4313887560 crossrefType "journal-article" @default.
• W4313887560 hasAuthorship W4313887560A5001241147 @default.
• W4313887560 hasAuthorship W4313887560A5041291871 @default.
• W4313887560 hasConcept C126322002 @default.
• W4313887560 hasConcept C164705383 @default.
• W4313887560 hasConcept C177713679 @default.
• W4313887560 hasConcept C2775935837 @default.
• W4313887560 hasConcept C2777093960 @default.
• W4313887560 hasConcept C2778094803 @default.
• W4313887560 hasConcept C2779161974 @default.
• W4313887560 hasConcept C2908647359 @default.
• W4313887560 hasConcept C71924100 @default.
• W4313887560 hasConcept C99454951 @default.
• W4313887560 hasConceptScore W4313887560C126322002 @default.
• W4313887560 hasConceptScore W4313887560C164705383 @default.
• W4313887560 hasConceptScore W4313887560C177713679 @default.
• W4313887560 hasConceptScore W4313887560C2775935837 @default.
• W4313887560 hasConceptScore W4313887560C2777093960 @default.
• W4313887560 hasConceptScore W4313887560C2778094803 @default.
• W4313887560 hasConceptScore W4313887560C2779161974 @default.
• W4313887560 hasConceptScore W4313887560C2908647359 @default.
• W4313887560 hasConceptScore W4313887560C71924100 @default.
• W4313887560 hasConceptScore W4313887560C99454951 @default.
• W4313887560 hasIssue "4" @default.
• W4313887560 hasLocation W43138875601 @default.
• W4313887560 hasLocation W43138875602 @default.
• W4313887560 hasOpenAccess W4313887560 @default.
• W4313887560 hasPrimaryLocation W43138875601 @default.
• W4313887560 hasRelatedWork W2009378781 @default.
• W4313887560 hasRelatedWork W2071515934 @default.
• W4313887560 hasRelatedWork W2110411269 @default.
• W4313887560 hasRelatedWork W2253309984 @default.
• W4313887560 hasRelatedWork W2346860639 @default.
• W4313887560 hasRelatedWork W2896445697 @default.
• W4313887560 hasRelatedWork W3174163922 @default.
• W4313887560 hasRelatedWork W4236317409 @default.
• W4313887560 hasRelatedWork W4283015630 @default.
• W4313887560 hasRelatedWork W4378448287 @default.
• W4313887560 hasVolume "20" @default.
• W4313887560 isParatext "false" @default.
• W4313887560 isRetracted "false" @default.
• W4313887560 workType "article" @default.